Chemical targeting of G-quadruplexes in telomeres and beyond for molecular cancer therapeutics

G-quadruplexes (G4s) are higher-order structures formed by guanine-rich sequences of nucleic acids, such as the telomeric 5 '-TTAGGG-3 '/5 '-UUAGGG-3 ' repeats and those in gene regulatory regions. G4s regulate various biological events, including replication, transcription, and translation. Imbalanced G4 dynamics is associated with diseases, such as cancer and neurodegenerative diseases. Telomestatin is a natural macrocyclic compound derived from Streptomyces anulatus 3533-SV4. It interacts with the guanine quartet via pi-pi stacking and potently stabilizes G4. Because G4 stabilization at the telomeric repeat inhibits the telomere-synthesizing enzyme telomerase, telomestatin was originally identified as a telomerase inhibitor. Whereas non-toxic doses of telomestatin induce gradual shortening of telomeres and eventual crisis in human cancer cells, higher doses trigger prompt replication stress and DNA damage responses, resulting in acute cell death. Suppression of the transcription and translation of G4-containing genes is also implicated in the anticancer effects of telomestatin. Because telomestatin is rare, labile, and insoluble, synthetic oxazole telomestatin derivatives have been developed and verified for their therapeutic efficacies in preclinical cancer models. Furthermore, a variety of G4-stabilizing compounds have been reported as promising seeds for molecular cancer therapeutics. To improve the design of future clinical studies, it will be important to identify predictive biomarkers of drug efficacy.

Automated summary

G-quadruplexes (G4s) are higher-order structures formed by guanine-rich sequences of nucleic acids, regulating biological events and associated with diseases like cancer. Telomestatin, a natural compound, stabilizes G4 structures and inhibits telomerase, potentially leading to anticancer effects. Synthetic derivatives have been developed to overcome the limitations of the natural compound and show promise in preclinical cancer models. Further research on G4-stabilizing compounds as potential cancer therapeutics and the identification of predictive biomarkers for drug efficacy are critical for future clinical studies.